20 Pediatric Blood Related 1 1 0 21 21 5 http://clinicaltrials.dfhcc.harvard.edu/trials/5 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with gemtuzumab may kill more cancer cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab in treating patients with newly diagnosed acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy and gemtuzumab to see how well they work compared with combination chemotherapy alone in treating young patients with newly diagnosed acute myeloid leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 3 175 http://clinicaltrials.dfhcc.harvard.edu/trials/175 Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known whether pegasparaginase is more effective than asparaginase when given together with combination chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying pegasparaginase to see how well it works compared with asparaginase when given together with combination chemotherapy in treating young patients with newly diagnosed acute lymphoblastic leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 3 54 http://clinicaltrials.dfhcc.harvard.edu/trials/54 Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving epratuzumab together with combination chemotherapy works in treating young patients with relapsed acute lymphoblastic leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 2 50 http://clinicaltrials.dfhcc.harvard.edu/trials/50 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin's disease who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 2 20 http://clinicaltrials.dfhcc.harvard.edu/trials/20 Fanconi Anemia Transplant Lacking Genotypically Identical Donor A research study for patients with Fanconi Anemia whose bone marrow has changed and now failed, giving rise to a pre-leukemia or leukemia. This study is a Phase II clinical trial in which patients will undergo allogenic transplant of stem cells, meaning they will receive bone marrow cells from a healthy donor. The purpose of this study is to see if transplant course of treatment will lower the risk of graft vs. host disease. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 2 1299 http://clinicaltrials.dfhcc.harvard.edu/trials/1299 Therapy for Pediatric Hodgkin Lymphoma With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 2 178 http://clinicaltrials.dfhcc.harvard.edu/trials/178 A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. The purpose of this study is to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe and effective in children with relapsed and refractory acute lymphoblastic leukemia or acute myelogenous leukemia. As of August 2007, this study is only recruiting patients for the Phase 2 portion of the study. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related Phase 1/Phase 2 37 http://clinicaltrials.dfhcc.harvard.edu/trials/37 Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methylprednisolone and antithymocyte globulin before transplant and peripheral blood cells that have been treated in the laboratory after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated peripheral blood cell infusion after donor stem cell transplant in treating patients with hematologic cancers or other diseases. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds Phase 1 79 http://clinicaltrials.dfhcc.harvard.edu/trials/79 Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors Phase 1 114 http://clinicaltrials.dfhcc.harvard.edu/trials/114 Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET) RATIONALE: Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer. PURPOSE: This clinical trial is studying neuropsychological and behavioral testing in young patients with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET). Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 121 http://clinicaltrials.dfhcc.harvard.edu/trials/121 Evaluating Dactinomycin and Vincristine in Young Patients With Cancer RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how dactinomycin and vincristine affect the body and how patients will respond to treatment. PURPOSE: This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors N/A 198 http://clinicaltrials.dfhcc.harvard.edu/trials/198 Rapamycin in Relapsed Acute Lymphoblastic Leukemia This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from working normally. It has been used for many years after kidney transplants to prevent rejection of the organ. Recent work suggests that rapamycin may also help treat leukemia and other cancers. Recruiting 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 212 http://clinicaltrials.dfhcc.harvard.edu/trials/212 Study of Late-Occurring Complications in Childhood Cancer Survivors RATIONALE: A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. PURPOSE: This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 348 http://clinicaltrials.dfhcc.harvard.edu/trials/348 Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin before and after transplant may stop this from happening. It is not yet known which treatment regimen is most effective in treating acute leukemia. PURPOSE: This randomized clinical trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 832 http://clinicaltrials.dfhcc.harvard.edu/trials/832 Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia RATIONALE: Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer treatment. PURPOSE: This clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 1177 http://clinicaltrials.dfhcc.harvard.edu/trials/1177 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1182 http://clinicaltrials.dfhcc.harvard.edu/trials/1182 Fludarabine-based Conditioning for Severe Aplastic Anemia The purpose of this study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia (SAA) transplanted with marrow from human leukocyte antigen (HLA)-compatible unrelated donors. Specifically, the study will address whether the addition of fludarabine to the conditioning regimen of Deeg et al. will permit reduction in the cyclophosphamide (CY) dose to a point where survival is maintained or improved and sustained hematopoietic engraftment is maintained or improved with reduced major regimen-related toxicity (RRT) and/or early death. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1187 http://clinicaltrials.dfhcc.harvard.edu/trials/1187 Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies. Recruiting 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1240 http://clinicaltrials.dfhcc.harvard.edu/trials/1240 MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in treating young patients with relapsed or refractory solid tumors or acute lymphoblastic leukemia. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1246 http://clinicaltrials.dfhcc.harvard.edu/trials/1246 A Study of Aprepitant (MK0869) and Fosaprepitant (MK0517) in Pediatric Patients Receiving Chemotherapy This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy induced nausea and vomiting in pediatric patients from 6 months to 17 years of age. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1421 http://clinicaltrials.dfhcc.harvard.edu/trials/1421 Evaluating the Safety and Effectiveness of Stem Cell Transplants From Unrelated Donors in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study) Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant is a treatment option for someone with a severe form of the disease. Prior to undergoing a transplant, people typically receive a conditioning regimen of high doses of chemotherapy and other medications to prepare the body to accept the transplant. A conditioning regimen that uses lower doses of chemotherapy and medications may be safer for transplant recipients. This study will evaluate the safety and effectiveness of blood stem cell transplants, using either bone marrow or umbilical cord blood from unrelated donors, in children with severe SCD who receive a reduced intensity conditioning regimen prior to the transplant. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant